Modifying PEST for Psoriatic Arthritis Screening
Recruiting · NCT06382051 · Interventional (participants receive a specific treatment) · Lead sponsor: Novartis Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
PEST Screening group
What this trial is about
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment.
- Adult patients at the time of informed consent signature
- Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
- Residents of Canada
- Key
Exclusion criteria
- Patients who have previously screened positive for PsA through PEST.
- Patients who have been diagnosed with PsA.
- Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
- Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.
Where it is running
30 locations listed.
- Novartis Investigative Site - Calgary, Alberta, Canada
- Novartis Investigative Site - Edmonton, Alberta, Canada
- Novartis Investigative Site - Edmonton, Alberta, Canada
- Novartis Investigative Site - Kelowna, British Columbia, Canada
- Novartis Investigative Site - Surrey, British Columbia, Canada
- Novartis Investigative Site - Winnipeg, Manitoba, Canada
- Novartis Investigative Site - Fredericton, New Brunswick, Canada
- Novartis Investigative Site - Barrie, Ontario, Canada
- Novartis Investigative Site - Greater Sudbury, Ontario, Canada
- Novartis Investigative Site - Hamilton, Ontario, Canada
- Novartis Investigative Site - Hamilton, Ontario, Canada
- Novartis Investigative Site - Hamilton, Ontario, Canada
- Novartis Investigative Site - London, Ontario, Canada
- Novartis Investigative Site - London, Ontario, Canada
- Novartis Investigative Site - Markham, Ontario, Canada
- Novartis Investigative Site - Ottawa, Ontario, Canada
- Novartis Investigative Site - Richmond Hill, Ontario, Canada
- Novartis Investigative Site - Stoney Creek, Ontario, Canada
- Novartis Investigative Site - Toronto, Ontario, Canada
- Novartis Investigative Site - Toronto, Ontario, Canada
- Novartis Investigative Site - Waterloo, Ontario, Canada
- Novartis Investigative Site - Montreal, Quebec, Canada
- Novartis Investigative Site - Montreal, Quebec, Canada
- Novartis Investigative Site - Montreal, Quebec, Canada
- Novartis Investigative Site - Québec, Quebec, Canada
- Novartis Investigative Site - Québec, Quebec, Canada
- Novartis Investigative Site - Ste-Foy, Quebec, Canada
- Novartis Investigative Site - Verdun, Quebec, Canada
- Novartis Investigative Site - Saskatoon, Saskatchewan, Canada
- Novartis Investigative Site - Saskatoon, Saskatchewan, Canada